多西环素联合乌司他丁治疗重症感染合并多器官功能障碍综合征的临床研究

Clinical research on doxycycline combined with ulinastatin in treatment of severe infection complicated with multiple organ dysfunction syndrome

目的探讨多西环素联合乌司他丁治疗重症感染合并多器官功能障碍综合征的临床疗效。方法选取2017年1月~2018年8月我院新诊断重症感染合并多器官功能障碍综合征患者50例,按随机数字表法分为观察组和对照组,每组25例。对照组给予多西环素治疗,观察组在此基础上给予乌司他丁治疗。观察两组治疗前与治疗后72h序贯器官衰竭评分(SOFA)、急性生理学及慢性健康状况评分系统(APACHEⅡ)、各项实验室指标的变化。结果治疗前,两组SOFA和APACHEⅡ得分、各项观察指标比较,差异无统计学意义(P>0.05);治疗后72h,观察组SOFA和APACHEⅡ得分、ALT、AST、BUN、Cr、LAC显著低于对照组,观察组PaO2、PaO2/FiO2显著高于对照组,差异有统计学意义(P<0.05);治疗后72h,两组CVP比较,差异无统计学意义(P>0.05)。结论多西环素联合乌司他丁可改善重症感染合并多器官功能障碍综合征患者疾病预后。

Objective To explore clinical curative effects of doxycycline combined with ulinastatin in treatment of severe infection complicated with multiple organ dysfunction syndrome.Methods 50 patients who were newly diagnosed as severe infection complicated with multiple organ dysfunction syndrome in our hospital from January 2017 to August 2018 were selected.According to the random number table method,they were divided into the observation group and the control group,with 25 cases in each group.The control group was treated with doxycycline while the observation group was treated with ulinastatin on basis of it.The changes of sequential organ failure assessment(SOFA),acute physiology and chronic health evaluation scoring system(APACHEⅡ)and laboratory indexes were observed before and 72h after treatment were observed.Results Before treatment,there were no statistically significant differences in SOFA scores,APACHEⅡscores and observative indexes between the two groups(P>0.05).At 72 h after treatment,the SOFA and APACHEⅡscores,ALT,AST,BUN,Cr and LAC in the observation group were significantly lower than those in the control group.PaO2 and PaO2/FiO2 in the observation group were significantly higher than the control group,and the difference was statistically significant(P<0.05).At 72 h after treatment,there was no significant difference in CVP between the two groups(P>0.05).Conclusion Doxycycline combined with ulinastatin improves disease prognosis in patients with severe infection complicated with multiple organ dysfunction syndrome.